Cervical Cancer

DNA Vaccine Expressing Human Papillomavirus Gene Invites Viral Immunity

Published in Gene Therapy Weekly, February 7th, 2002

by Sonia Nichols, senior medical writer - An experimental vaccine containing genes for the human papillomavirus 16-L1 (HPV16-L1) protein has shown promising results for halting tumor growth and extending survival in mice.

Researchers say that the plasmid DNA vaccine might be effective for preventing human HPV16 infection, a disease associated with the formation of cervical cancer in women.

According to Leticia Rocha-Zavaleta and associates at the Universidad Nacional Autonoma de Mexcio, Mexico City, the plasmid DNA vaccine worked well when administered either orally, subcutaneously, or intramuscularly to mice, generating sizeable numbers of IgG...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2002-02-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry